ImaCor Inc., developer of the first and only hemodynamic transesophageal echocardiographic (hTEE™) management device, announced a group of new customers:
- Walter Reed National Military Medical Center (Bethesda, MD)
- Thomas Jefferson University Medical Center (Philadelphia, PA)
- Wake Forest Baptist Medical Center (Winston-Salem, NC)
- New York University Langone Medical Center (New York, NY)
"The ClariTEE probe is changing our ICU practice," commented Commander Robert F. Browning, Jr, MD*, Chief of Critical Care at Walter Reed National Military Medical Center."The fundamental difference between conventional diagnostic TEE and hTEE is a static-versus-dynamic monitoring approach. This technology enables us to tailor our therapies more precisely and assess the effectiveness of these therapies, which is absolutely critical."
hTEE management is enabled via the Zura™ platform and ClariTEE® probe, the first and only of its kind designed and optimized for the critical care setting.With minimal operator-dependence, continual availability, and ease of repeatability, the ClariTEE may remain indwelling for up to 72 hours to provide direct visualization of the heart.
"It is an honor to work with these outstanding clinicians and medical centers in addressing a previously unmet need in medical, trauma, and perioperative critical care," said Peter Pellerito, ImaCor's President/CEO. "Through comprehensive clinical support and education, we are committed to ensuring that all customers realize the full potential of hTEE management in successfully treating high-acuity patients."
"We developed the Zura system and ClariTEE probe to make TEE for hemodynamic management readily available to intensivists," said Harold M. Hastings, PhD, Co-Founder and Chief Technical Officer of ImaCor. "It is rewarding to see the recognition of the utility of our system in an ever growing group of customers."
*The views expressed do not reflect the official policy or position of the Department of the Navy, Department of Defense, or the U.S. Government.
ImaCor Inc. is a privately held company headquartered in Garden City, NY. The company designs, manufactures, and distributes advanced solutions for hemodynamic assessment in the critical care environment for the purpose of improving patient outcomes and optimizing utilization of healthcare costs. ImaCor manufactures the ClariTEE® probe, the only miniaturized, indwelling TEE probe suitable for long-term clinical settings. hTEE™, Zura™ and ClariTEE® are trademarks of ImaCor, Inc. http://www.imacorinc.com.